| Combined Substances Worksheet | Combined List June 10th (requires access request) Updated to include more countries June 10th Tabs: - Single Count Substances: List of substances that currently exist in one extension.
- Action
- Each country representative has been sent a link to a spreadsheet with the list of substances within their extension which have been used to model medicinal products. Please review the substances for relevance in the international edition. Column B has been provided for comments.
- Coincidences pending resolution: Substances in multiple countries where promotion will be required
- Action:
- SNOMED International is progressing (CRS for Managed Service or RF2 import for non-Managed Service)
- Coincidences already resolved: Substances in extensions where there is an International concept
- Action: Individual extensions to review and inactivate extension concept as there is an International concept.
|
2 Comments
Monica Harry
Dear members of the DEUSG,
I sent a message using the SHARE function hereon but just to make sure you are in the know, I will repeat the message here.
In order to streamline the process: Please do not submit any CRS requests for substance content at this time whether for net new, or content for promotion, or change requests.
We have all the content from extensions and are continuing our review. Please complete review of any content you own. Following review, we will promote these concepts via the INFRA ticket system directly into the Authoring Platform. We track progress and will provide feedback in the google sheet and at the next meeting. -
Thanks for your co-operation and understanding.
Monica
Marta Pavón Garrido
Dear Monica,
We fully understand the importance of streamlining the process and avoiding duplication. However, the Spanish NRC submits monthly CRS requests specifically for new active substances needed to model newly created MP containing concepts representing medicines recently authorized at the EU level and commercialized in Spain. If we are unable to submit these requests, we are forced to create these concepts in our national extension and this approach increases the risk of duplication across extensions, exacerbating the problem we are trying to resolve.
Therefore, we kindly ask you to reconsider accepting CRS submissions for new active substances, provided we verify that these concepts are present neither in the International Edition nor in other national extensions. Each request is accompanied by the EMA Summary of Product Characteristics as supporting documentation.
Thank you for your understanding and consideration.
Marta Pavón Garrido
Head of Service
Spanish SNOMED CT National Release Center